抗PARC抗体(Anti-PARC, Human, Goat-Poly, Biotin antibody)

• 価格
• Product Details
• Applications and Data
• References
• Related Research Areas
• Related Product & Information
• Citations

価格

目次に戻る

Product Details

Species Reactivity	Human
Label	Biotin
Immunogen	E. coli-derived recombinant human CCL18/PARCAla21-Ala89Accession # P55774
Source	Polyclonal Goat IgG
Purification	Antigen Affinity-purified
Specificity	Detects human CCL18/PARC in ELISAs and Western blots. In sandwich ELISAs, less than 0.1% cross-reactivity with recombinant human (rh) HCC‑1, rhMPIF‑1, rhMIP‑1 alpha, recombinant mouse (rm) MIP‑1 alpha, rhMIP‑1 beta, rmMIP‑1 beta, recombinant viral (rv) MIP‑I, rvMIP‑II, and rhMIP‑1δ is observed.

目次に戻る

Applications and Data

	Recommended Concentration	Sample
Western Blot	0.1 µg/mL	Recombinant Human CCL18/PARC (Catalog # 394-PA)
Intracellular Staining by Flow Cytometry	2.5 µg/106 cells	Human monocyte-derived dendritic cells treated with Recombinant Human IL‑4 (Catalog # 204-IL), Recombinant Human GM-CSF (Catalog # 215-GM), Recombinant Human TNF‑ alpha (Catalog # 210-TA), Recombinant Human IL‑1 beta /IL‑1F2 (Catalog # 201-LB), and LPS fixed with paraformaldehyde and permeabilized with saponin
Human CCL18/PARC Sandwich Immunoassay	Reagent
ELISA Capture (Matched Antibody Pair)	2-8 µg/mL	Human CCL18/PARC Antibody (Catalog #MAB394 )
ELISA Detection (Matched Antibody Pair)	0.1-0.4 µg/mL	Human CCL18/PARC Biotinylated Antibody (Catalog #BAF394 )
ELISA Standard		Recombinant Human CCL18/PARC Protein (Catalog #394-PA )
Please Note: Optimal dilutions should be determined by each laboratory for each application.General Protocolsare available in the Technical Information section on our website.		Preparation and Storage
Reconstitution	Reconstitute at 0.2 mg/mL in sterile PBS.	Reconstitution Buffer Available
Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied.
1 month, 2 to 8 °C under sterile conditions after reconstitution.
6 months, -20 to -70 °C under sterile conditions after reconstitution.
Background: CCL18/PARC	CCL18, also known as alternative macrophage activation-associated CC chemokine (AMAC)-1, macrophage inflammatory protein (MIP)-4, and dendritic cell chemokine (DC-CK1), is a novel CC chemokine that is highly homologous to MIP-1 alpha (61% amino acid (aa) sequence identity). CCL18 cDNA encodes an 89 aa residue precursor protein with a 20 aa putative signal peptide that is cleaved to generate a 69 aa residue mature protein which lacks potential glycosylation sites. In vitro, CCL18 mRNA expression is induced in alternatively activated macrophages by Th2 cytokines such as IL-4, IL-10, and IL-13, and inhibited by IFN‑ gamma. CCL18 mRNA is also expressed by GM-CSF/IL-4-induced monocyte-derived dendritic cells. In vivo, CCL18 is highly expressed in lung and placenta but is not expressed in epidermal Langerhans cells. Recombinant CCL18 has been shown to chemoattract naive T cells but not monocytes or neutrophils.

目次に戻る

References

Adema, G. et al. (1997) Nature 387:713.
Kodelja, V. et al. (1998) J. Immunol. 160:141.
Entrez Gene IDs:	6362 (Human)
Alternate Names:	Alternative macrophage activation-associated CC chemokine 1; AMAC-1; AMAC1CC chemokine ligand 18; AMAC-1Small-inducible cytokine A18; CCL18; chemokine (C-C motif) ligand 18 (pulmonary and activation-regulated); CKb7; DC-CK1; DC-CK1CC chemokine PARC; DCCK1Macrophage inflammatory protein 4; Dendritic cell chemokine 1; MIP4; MIP-4; MIP-4C-C motif chemokine 18; PARC; PARCPulmonary and activation-regulated chemokine; SCYA18chemokine (C-C), dendritic; small inducible cytokine A18; small inducible cytokine subfamily A (Cys-Cys), member 18, pulmonary andactivation-regulated

目次に戻る

Related Research Areas

CC Chemokines and Receptors

Chemokines and Receptors

Macrophage Activation Markers

Prominent Levels of the Profibrotic Chemokine CCL18 during Peritonitis: In Vitro Downregulation by Vitamin D Receptor Agonists Authors: M Ossorio, V Martínez, MA Bajo, G Del Peso, MJ Castro, S Romero, R Selgas, T Bellón Biomed Res Int, 2018;2018(0):6415892. Species: Human Sample Type: Whole Cells Application: ICC

目次に戻る

Related Product & Information

Background

CCL18/PARC

background_content

Background: CCL18/PARC CCL18, also known as alternative macrophage activation-associated CC chemokine (AMAC)-1, macrophage inflammatory protein (MIP)-4, and dendritic cell chemokine (DC-CK1), is a novel CC chemokine that is highly homologous to MIP-1 alpha (61% amino acid (aa) sequence identity). CCL18 cDNA encodes an 89 aa residue precursor protein with a 20 aa putative signal peptide that is cleaved to generate a 69 aa residue mature protein which lacks potential glycosylation sites. In vitro, CCL18 mRNA expression is induced in alternatively activated macrophages by Th2 cytokines such as IL-4, IL-10, and IL-13, and inhibited by IFN‑ gamma. CCL18 mRNA is also expressed by GM-CSF/IL-4-induced monocyte-derived dendritic cells. In vivo, CCL18 is highly expressed in lung and placenta but is not expressed in epidermal Langerhans cells. Recombinant CCL18 has been shown to chemoattract naive T cells but not monocytes or neutrophils.

目次に戻る

Citations

1. Prominent Levels of the Profibrotic Chemokine CCL18 during Peritonitis: In Vitro Downregulation by Vitamin D Receptor Agonists
   Authors: M Ossorio, V Martínez, MA Bajo, G Del Peso, MJ Castro, S Romero, R Selgas, T Bellón
   Biomed Res Int, 2018;2018(0):6415892.
   Species: Human
   Sample Type: Whole Cells
   Application: ICC


2. Multiplex serum protein analysis reveals potential mechanisms and markers of response to hyperimmune caprine serum in systemic sclerosis
   Authors: N Quillinan, KE Clark, B Youl, J Vernes, D McIntosh, S Haq, CP Denton
   Arthritis Res. Ther, 2017;19(1):45.
   Species: Human
   Sample Type: Serum
   Application: ELISA detection


3. Potential biomarkers of osteonecrosis in Gaucher disease.
   Authors: Pavlova EV, Deegan PB, Tindall J, McFarlane I, Mehta A, Hughes D, Wraith JE, Cox TM
   Blood Cells Mol. Dis., 2011;46(1):27-33.
   Species: Human
   Sample Type: Serum
   Application: Luminex Development


4. Osseous manifestations of adult Gaucher disease in the era of enzyme replacement therapy.
   Authors: Deegan PB, Pavlova E, Tindall J
   Medicine (Baltimore), 2011;90(1):52-60.
   Species: Human
   Sample Type: Plasma
   Application: Other: See notes

目次に戻る